loading
Praxis Precision Medicines Inc stock is traded at $274.48, with a volume of 75,992. It is up +0.81% in the last 24 hours and up +62.03% over the past month. Praxis Precision Medicines Inc is a clinical-stage biopharmaceutical company. The firm is engaged in translating genetic insights into the development of therapies for patients affected by central nervous system disorders characterized by a neuronal excitation-inhibition imbalance. The company has generated three clinical-stage product candidates, ulixacaltamide (formerly known as PRAX-944), vormatrigine (formerly known as PRAX-628), and relutrigine (formerly known as PRAX-562), as well as PRAX-020 which has been in-licensed by UCB Biopharma SRL, or UCB.
See More
Previous Close:
$272.92
Open:
$273
24h Volume:
75,992
Relative Volume:
0.08
Market Cap:
$6.87B
Revenue:
$1.77M
Net Income/Loss:
$-123.74M
P/E Ratio:
-29.93
EPS:
-9.17
Net Cash Flow:
$-95.21M
1W Performance:
-0.46%
1M Performance:
+62.03%
6M Performance:
+549.79%
1Y Performance:
+259.54%
1-Day Range:
Value
$268.57
$279.33
1-Week Range:
Value
$262.31
$282.00
52-Week Range:
Value
$26.70
$282.99

Praxis Precision Medicines Inc Stock (PRAX) Company Profile

Name
Name
Praxis Precision Medicines Inc
Name
Phone
617-300-8460
Name
Address
99 HIGH STREET, 30TH FLOOR, BOSTON
Name
Employee
82
Name
Twitter
Name
Next Earnings Date
2024-11-06
Name
Latest SEC Filings
Name
PRAX's Discussions on Twitter

Compare PRAX with other stocks

Stocks Price Market Cap Revenue Net Income Cash Flow EPS
Biotechnology icon
PRAX
Praxis Precision Medicines Inc
274.91 6.82B 1.77M -123.74M -95.21M -9.17
Biotechnology icon
VRTX
Vertex Pharmaceuticals Inc
458.22 115.75B 11.74B 3.68B 3.34B 14.19
Biotechnology icon
REGN
Regeneron Pharmaceuticals Inc
780.00 80.71B 14.25B 4.58B 3.88B 41.77
Biotechnology icon
ALNY
Alnylam Pharmaceuticals Inc
410.70 52.88B 3.21B 43.57M 221.36M 0.2405
Biotechnology icon
ARGX
Argen X Se Adr
854.66 52.64B 3.06B 1.28B 447.35M 19.67
Biotechnology icon
INSM
Insmed Inc
177.99 37.29B 447.02M -1.18B -906.14M -6.1812

Praxis Precision Medicines Inc Stock (PRAX) Upgrades & Downgrades

Date Action Analyst Rating Change
Dec-15-25 Reiterated Oppenheimer Outperform
Nov-19-25 Initiated BTIG Research Buy
Jun-02-25 Resumed Oppenheimer Outperform
May-07-25 Initiated Chardan Capital Markets Buy
Mar-03-25 Reiterated H.C. Wainwright Buy
Feb-11-25 Initiated Deutsche Bank Buy
Aug-05-24 Initiated Oppenheimer Outperform
Jun-24-24 Initiated Needham Buy
Jun-18-24 Initiated Guggenheim Buy
May-01-24 Initiated Robert W. Baird Outperform
Sep-19-23 Initiated Truist Buy
Jun-06-22 Downgrade Wedbush Outperform → Neutral
Dec-16-21 Initiated H.C. Wainwright Buy
Aug-26-21 Initiated BofA Securities Buy
Apr-26-21 Initiated William Blair Outperform
Nov-11-20 Initiated Wedbush Outperform
Nov-10-20 Initiated Cowen Outperform
Nov-10-20 Initiated Evercore ISI Outperform
Nov-10-20 Initiated Piper Sandler Overweight
View All

Praxis Precision Medicines Inc Stock (PRAX) Latest News

pulisher
Dec 21, 2025

Aug Wrap: Why Praxis Precision Medicines Inc. stock could be next big winnerMarket Risk Analysis & Fast Entry High Yield Tips - ulpravda.ru

Dec 21, 2025
pulisher
Dec 20, 2025

Praxis Precision Medicines (PRAX) Price Target Increased by 38.02% to 410.52 - Nasdaq

Dec 20, 2025
pulisher
Dec 20, 2025

Assenagon Asset Management S.A. Has $21.72 Million Stock Position in Praxis Precision Medicines, Inc. $PRAX - MarketBeat

Dec 20, 2025
pulisher
Dec 20, 2025

What dividend safety score for Praxis Precision Medicines Inc. stock2025 Earnings Impact & Free Community Consensus Stock Picks - Улправда

Dec 20, 2025
pulisher
Dec 19, 2025

Can Praxis Precision Medicines Inc. stock continue upward trendChart Signals & Daily Growth Stock Investment Tips - ulpravda.ru

Dec 19, 2025
pulisher
Dec 19, 2025

Why Praxis Precision Medicines Inc. stock appeals to dividend seekersTrade Performance Summary & High Conviction Trade Alerts - Улправда

Dec 19, 2025
pulisher
Dec 19, 2025

Can Praxis Precision Medicines Inc. stock beat market expectations this quarterDollar Strength & Advanced Technical Analysis Signals - DonanımHaber

Dec 19, 2025
pulisher
Dec 19, 2025

How strong is Praxis Precision Medicines Inc. stock balance sheetJuly 2025 Movers & Fast Gain Stock Trading Tips - DonanımHaber

Dec 19, 2025
pulisher
Dec 19, 2025

How Praxis Precision Medicines Inc. stock benefits from global expansionWeekly Trade Report & Weekly Top Stock Performers List - ulpravda.ru

Dec 19, 2025
pulisher
Dec 19, 2025

Will Praxis Precision Medicines Inc. stock benefit from commodity pricesSwing Trade & Daily Technical Forecast Reports - Bölüm Sonu Canavarı

Dec 19, 2025
pulisher
Dec 18, 2025

Why Praxis Precision Medicines Inc. stock could be next big winner2025 Fundamental Recap & AI Enhanced Trading Signals - Улправда

Dec 18, 2025
pulisher
Dec 16, 2025

Medical Stocks To Follow NowDecember 5th - MarketBeat

Dec 16, 2025
pulisher
Dec 16, 2025

Praxis Precision Medicines stock hits 52-week high at 279.0 USD - Investing.com India

Dec 16, 2025
pulisher
Dec 15, 2025

Has Praxis Precision Medicines Rally Gone Too Far or Is the Market Still Missing Something - Yahoo Finance

Dec 15, 2025
pulisher
Dec 15, 2025

Oppenheimer Maintains Praxis Precision Medicines (PRAX) Outperform Recommendation - Nasdaq

Dec 15, 2025
pulisher
Dec 15, 2025

Oppenheimer Raises Price Target for Praxis Precision Medicine (P - GuruFocus

Dec 15, 2025
pulisher
Dec 15, 2025

Praxis Precision Medicines (NASDAQ:PRAX) Sets New 12-Month HighWhat's Next? - MarketBeat

Dec 15, 2025
pulisher
Dec 15, 2025

Oppenheimer Adjusts Praxis Precision Medicines PT to $750 From $250, Maintains Outperform Rating - marketscreener.com

Dec 15, 2025
pulisher
Dec 15, 2025

Praxis Precision Medicines stock hits 52-week high at 279.0 USD By Investing.com - Investing.com South Africa

Dec 15, 2025
pulisher
Dec 15, 2025

Praxis Precision Medicines stock price target raised to $750 from $250 at Oppenheimer - Investing.com Australia

Dec 15, 2025
pulisher
Dec 15, 2025

Praxis Precision Medicines stock price target raised to $750 from $250 at Oppenheimer By Investing.com - Investing.com South Africa

Dec 15, 2025
pulisher
Dec 14, 2025

Praxis Precision Medicines Inc. (PRAX) secures analyst confidence after key FDA and trial wins - MSN

Dec 14, 2025
pulisher
Dec 14, 2025

Best Pharmaceutical Stocks To Watch TodayDecember 5th - MarketBeat

Dec 14, 2025
pulisher
Dec 13, 2025

(PRAX) Price Dynamics and Execution-Aware Positioning - news.stocktradersdaily.com

Dec 13, 2025
pulisher
Dec 12, 2025

Praxis Precision Medicines Plans New Drug Application - The Globe and Mail

Dec 12, 2025
pulisher
Dec 12, 2025

Praxis Precision to file an NDA for relutrigine in encephalopathies in 2026 - Yahoo Finance

Dec 12, 2025
pulisher
Dec 12, 2025

Deutsche Bank Raises Price Target on Praxis Precision Medicines to $313 From $303, Keeps Buy Rating - marketscreener.com

Dec 12, 2025
pulisher
Dec 12, 2025

OCONNOR A Distinct Business Unit of UBS ASSET MANAGEMENT AMERICAS LLC Reduces Stock Position in Praxis Precision Medicines, Inc. $PRAX - MarketBeat

Dec 12, 2025
pulisher
Dec 12, 2025

Praxis tees up another approval filing; Geron turns to layoffs - Yahoo Finance

Dec 12, 2025
pulisher
Dec 11, 2025

Praxis Precision Medicines (PRAX): Revisiting Valuation After Major FDA Progress and Positive CNS Trial Updates - Sahm

Dec 11, 2025
pulisher
Dec 11, 2025

Praxis Precision Medicines updates clinical trial design and regulatory plans - Investing.com

Dec 11, 2025
pulisher
Dec 11, 2025

Praxis, FDA agree on pivotal trial changes for encephalopathy asset elsunersen - MSN

Dec 11, 2025
pulisher
Dec 11, 2025

Praxis Precision Medicines Confirms FDA Filing Path for New Drug Application of Relutrigine in Early 2026 - Quiver Quantitative

Dec 11, 2025
pulisher
Dec 11, 2025

TD Cowen lifts Praxis Precision Medicines Inc. (PRAX) price target amid NDA for essential tremor treatment - MSN

Dec 11, 2025
pulisher
Dec 11, 2025

Praxis Precision Medicines Announces Plans to File an NDA - GlobeNewswire

Dec 11, 2025
pulisher
Dec 11, 2025

TD Cowen Lifts Praxis Precision Medicines Inc. (PRAX) Price Target amid NDA for Essential Tremor Treatment - Insider Monkey

Dec 11, 2025
pulisher
Dec 11, 2025

HighVista Strategies LLC Buys 28,002 Shares of Praxis Precision Medicines, Inc. $PRAX - MarketBeat

Dec 11, 2025
pulisher
Dec 10, 2025

Praxis a new buy at BTIG as biotech is a top pick for 2026 - MSN

Dec 10, 2025
pulisher
Dec 10, 2025

Velan Capital Investment Management LP Sells 35,666 Shares of Praxis Precision Medicines, Inc. $PRAX - MarketBeat

Dec 10, 2025
pulisher
Dec 10, 2025

Stempoint Capital LP Takes $1.36 Million Position in Praxis Precision Medicines, Inc. $PRAX - MarketBeat

Dec 10, 2025
pulisher
Dec 10, 2025

Maven Securities LTD Buys Shares of 5,000 Praxis Precision Medicines, Inc. $PRAX - MarketBeat

Dec 10, 2025
pulisher
Dec 09, 2025

Praxis Precision Medicines Says FDA Agrees to Proposed Changes to Embrave3 Trial Design - marketscreener.com

Dec 09, 2025
pulisher
Dec 09, 2025

PRAX Adjusts EMBRAVE3 Study Design After FDA Meeting - GuruFocus

Dec 09, 2025
pulisher
Dec 09, 2025

Praxis Precision Medicines Announces FDA Approval for EMBRAVE3 Trial Design Change for Elsunersen in SCN2A Developmental and Epileptic Encephalopathy - Quiver Quantitative

Dec 09, 2025
pulisher
Dec 09, 2025

Praxis Precision Medicines announces alignment with FDA - marketscreener.com

Dec 09, 2025
pulisher
Dec 09, 2025

PRAX Stock Research: Jefferies Raises Price Target by 50% on Dec - GuruFocus

Dec 09, 2025
pulisher
Dec 09, 2025

Praxis Precision Medicines Announces Alignment with FDA on - GlobeNewswire

Dec 09, 2025
pulisher
Dec 09, 2025

Guggenheim Maintains Praxis Precision Medicines (PRAX) Buy Recommendation - Nasdaq

Dec 09, 2025
pulisher
Dec 09, 2025

PRAX Stock Skyrockets 520% in 3 Months: Here's What You Need to Know - Eastern Progress

Dec 09, 2025
pulisher
Dec 09, 2025

Praxis Precision Medicines (PRAX) Soars on FDA Momentum and 760-Dollar Target: December 9, 2025 Stock Deep Dive - ts2.tech

Dec 09, 2025
pulisher
Dec 09, 2025

Vivo Capital LLC Takes Position in Praxis Precision Medicines, Inc. $PRAX - MarketBeat

Dec 09, 2025

Praxis Precision Medicines Inc Stock (PRAX) Financials Data

Revenue

loading

Net Income

loading

Cash Flow

loading

EPS

loading

Praxis Precision Medicines Inc Stock (PRAX) Insider Trading

Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total
Nemiroff Alex
General Counsel and Secretary
Nov 20 '25
Sale
193.09
25,130
4,852,256
20,832
Mastrocola Lauren
Principal Accounting Officer
Nov 20 '25
Option Exercise
61.12
13,600
831,257
24,042
Mastrocola Lauren
Principal Accounting Officer
Nov 20 '25
Sale
192.08
13,600
2,612,244
10,442
$38.57
price up icon 0.08%
$101.09
price down icon 1.51%
$32.51
price up icon 0.40%
$92.08
price down icon 0.51%
biotechnology ONC
$314.21
price down icon 0.35%
$178.13
price up icon 1.92%
Cap:     |  Volume (24h):